Amarin Corp. (AMRN) Misses Q4 EPS by 3c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations
February 28, 2017 6:00 AM EST$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015
 REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Final Target Event Near the End of 2017
Management to Host Conference Call at 7:30 a.m. ET Today
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial... More
